CTOs on the Move

Highland Therapeutics

www.highlandtherapeutics.com

 
Highland Therapeutics Inc., a Toronto-based specialty pharmaceutical company. It is a specialty pharmaceutical company leveraging its proprietary technologies to optimize the delivery of previously approved drug products.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Highland Therapeutics raised $25M on 06/24/2015
Highland Therapeutics raised $200M on 01/24/2017

Similar Companies

PDi-Pharmaceuticals

PDi-Pharmaceuticals is a Aurora, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verinetics

Verinetics is a company that provides the DispenSecur solution for Opioid Medication Management, which offers better control for controlled substances and integrates into existing pharmacy and patient management practices.

Vit-Best

Vit Best Nutrition is a fully integrated contract manufacturer for the Nutritional Supplement Industry, offering a wide range of production capabilities for tablets, capsules, and powders.

CARGO Therapeutics

CARGO Therapeutics is a biotechnology company that is developing and delivering CAR T cell therapies to cure more cancer patients. Their cell therapies focus on addressing the primary mechanisms of failure, or resistance and relapse, to the currently a...

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.